scholarly journals Gait Variability, Not Walking Speed, Is Related to Cognition in Adolescents With Multiple Sclerosis

2018 ◽  
Vol 34 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Alon Kalron ◽  
Anat Achiron ◽  
Shay Menascu
Keyword(s):  
Multiple Sclerosis ◽  
Walking Speed ◽  
Gait Variability

Walking capacities in multiple sclerosis measured by global positioning system odometer

2007 ◽  
Vol 13 (2) ◽  
pp. 220-223 ◽  
Author(s):  
A Créange ◽  
I Serre ◽  
M Levasseur ◽  
D Audry ◽  
A Nineb ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Global Positioning System ◽  
Walking Speed ◽  
Walking Distance ◽  
Expanded Disability Status Scale ◽  
Satellite Technology ◽  
Promising Tool ◽  
Disability Status ◽  
Global Positioning

We used a global positioning satellite technology odometer to determine the maximum objective walking distance capacity (MOWD) of patients with multiple sclerosis (MS). The MOWD correlated with Expanded Disability Status Scale (EDSS) score (r2 =0.41; P < 0.0001), the MSWS-12 scale (r2 = 0.46; P < 0.0001), time to walk 10 m (r2 = 0.51; P < 0.02) and walking speed (r2 =0.75; P < 0.001). Limitation of walking capacities was measurable up to 4550 m, strikingly above the 500-m limit of the EDSS. This objective odometer is a promising tool for evaluation and follow-up of patients with MS. Multiple Sclerosis 2007; 13: 220–223. http://msj.sagepub.com

Efficacy and safety of fampridine for walking disability in multiple sclerosis

2020 ◽  
Vol 10 (5) ◽  
pp. 277-287
Author(s):  
Eva Costa Arpín
Keyword(s):  
Multiple Sclerosis ◽  
Back Pain ◽  
Walking Speed ◽  
Development Phase ◽  
Concomitant Treatment ◽  
Efficacy And Safety ◽  
Real World Setting ◽  
Number Of Patients ◽  
History Of ◽  
Clinically Significant

Fampridine is the only drug approved for the treatment of walking impairment in multiple sclerosis. Around a third of the patients on treatment obtained an improvement in walking speed during the development phase. The effects are clinically significant, appear soon after the start of the treatment and are long-lasting, but disappear soon after the drug is withdrawn. In the real-world setting, the number of patients with a significant response to the treatment seems to be higher (around 70%). The tolerance is good, with mild to moderate, and transient adverse events. The most commonly reported are insomnia, headache, fatigue, back pain, dizziness, nausea and balance disorders. The main contraindications are a history of seizures, renal impairment and concomitant treatment with OCT2 inhibitors.

scholarly journals Factors for Lower Walking Speed in Persons with Multiple Sclerosis

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Leandro Alberto Calazans Nogueira ◽  
Luciano Teixeira dos Santos ◽  
Pollyane Galinari Sabino ◽  
Regina Maria Papais Alvarenga ◽  
Luiz Claudio Santos Thuler
Keyword(s):  
Physical Activity ◽  
Multiple Sclerosis ◽  
Physical Activity Level ◽  
Walking Speed ◽  
Motor Planning ◽  
Activity Level ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Balance Confidence ◽  
Significant Difference

Objective. The purpose of this study was to analyze factors related to lower walking speed in persons with multiple sclerosis (PwMS).Methods. A cross-sectional survey was conducted. The study participants were 120 consecutive PwMS, who were able to walk, even with device assistance. Demographic and clinical data were collected. Walking speed was measured in 10 m walk test. Possible factors were assessed: disability, fatigue, visual functioning, balance confidence, physical activity level, walking impact, cognitive interference, and motor planning. A forward linear multiple regression analysis examined the correlation with lower speed.Results. Lower walking speed was observed in 85% of the patients. Fatigue (41%), recurrent falls (30%), and balance problems were also present, even with mild disability (averageEDSS=2.68). A good level of physical activity was noted in most of the subjects. Dual-task procedure revealed 11.58% of walking speed reduction. Many participants (69.57%) imagined greater walking speed than motor execution (mean ≥ 28.42%). Physical activity level was the only characteristic that demonstrated no significant difference between the groups (lower versus normal walking speed). Many mobility measures were correlated with walking speed; however, disability, balance confidence, and motor planning were the most significant.Conclusions. Disability, balance confidence, and motor planning were correlated with lower walking speed.

Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience

2020 ◽  
pp. 135245852093691
Author(s):  
Justin R Abbatemarco ◽  
Austin Griffin ◽  
Noble G Jones ◽  
Jennifer Hartman ◽  
Keith McKee ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Complication Rate ◽  
Walking Speed ◽  
Cox Model ◽  
Intrathecal Baclofen ◽  
Mixed Effect ◽  
Ambulatory Status ◽  
Single Center Experience ◽  
Effect Model ◽  
Multiple Sclerosis Patients

Background: Intrathecal baclofen (ITB) is traditionally reserved for non-ambulatory patients. Objective: To investigate outcomes of ITB in ambulatory multiple sclerosis (MS) patients. Methods: Changes in outcome measures were estimated by a mixed effect model, while the complication rate was calculated using a logistic regression. Predictors of non-ambulatory status were identified by Cox model. Results: In all, 256 patients received an ITB test injection and 170 underwent ITB surgery. Aggregate Modified Ashworth Scale (MAS) scores for the ambulatory ITB cohort decreased from 13.5 ± 6.96 to 4.54 ± 4.18 at 5 years ( p < 0.001). There was no significant change in walking speed 1 year post ITB surgery (0.45 m/second ± 0.30 vs 0.38 m/second ± 0.39, p = 0.80) with 77.8% of patients remaining ambulatory which decreased to 41.7% at year 5. Longer MS disease duration (hazard ratio (HR): 1.04; 95% confidence interval (CI): 1.01–1.07; p = 0.018) and lower hip flexor strength (HR: 0.40; 95% CI: 0.27–0.57; p < 0.001) predicted non-ambulatory status after surgery. Complications were more likely in the ambulatory cohort (odds ratio (OR): 3.30, 95% CI: 2.17–5.02; p = 0.017). Conclusion: ITB is effective for ambulatory MS patients without compromising short-term walking speed, although a higher complication rate was observed in this cohort.

scholarly journals Effect of a strong desire to void on walking speed in individuals with multiple sclerosis and urinary disorders

2020 ◽  
Vol 63 (2) ◽  
pp. 106-110
Author(s):  
Claire Hentzen ◽  
Nicolas Turmel ◽  
Camille Chesnel ◽  
Audrey Charlanes ◽  
Frédérique Le Breton ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Walking Speed ◽  
Urinary Disorders

scholarly journals Depression in multiple sclerosis across the adult lifespan

2020 ◽  
pp. 135245852097930
Author(s):  
Carol K Chan ◽  
Fan Tian ◽  
Daniela Pimentel Maldonado ◽  
Ellen M Mowry ◽  
Kathryn C Fitzgerald
Keyword(s):  
Multiple Sclerosis ◽  
Depressive Symptoms ◽  
Regression Models ◽  
Walking Speed ◽  
Age Groups ◽  
Adult Age ◽  
Adult Lifespan ◽  
Prevalence Of Depression ◽  
Z Scores ◽  
The Relationship

Objectives: The objective of this study is to examine the burden of depressive symptoms across the adult age span in people with multiple sclerosis (MS) and test if the relationship between depressive symptoms and MS characteristics vary across age groups. Methods: In analyses of the MS Partners Advancing Technology and Health Solutions (MS PATHS) network of adults with MS, we compared the prevalence of depression in MS PATHS with non-MS controls across age and evaluated for effect modification by age in the association between depressive symptoms and clinical and neuroperformance measures via multivariable-adjusted regression models. Results: In total, 13,821 individuals with MS were included. The prevalence of depression was higher in MS versus non-MS controls, but was similar between men/women across age. The association between depression and processing speed (PST; p for interaction = 0.009) or walking speed ( p for interaction = 0.04) varied by age. For example, younger depressed individuals had 0.45 standard deviation (SD) (95% confidence interval (CI) = −0.62, −0.29) worse PST Z-scores versus non-depressed younger participants, whereas older depressed individuals had 0.20 SD (95% CI = −0.32, −0.08) worse PST Z-scores versus non-depressed older participants. Conclusion: Depressive symptoms and age should be considered when interpreting measures of walking speed and cognitive function; these findings may have implications for analyses of neuroperformance change.

scholarly journals Quantitative sensory and motor measures detect change over time and correlate with walking speed in individuals with multiple sclerosis

2015 ◽  
Vol 4 (1) ◽  
pp. 67-74 ◽  
Author(s):  
Kathleen M. Zackowski ◽  
Joseph I. Wang ◽  
John McGready ◽  
Peter A. Calabresi ◽  
Scott D. Newsome
Keyword(s):  
Multiple Sclerosis ◽  
Walking Speed ◽  
Change Over Time ◽  
Over Time

Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study

2007 ◽  
Vol 13 (2) ◽  
pp. 224-231 ◽  
Author(s):  
Barbara Giesser ◽  
Janell Beres-Jones ◽  
Amy Budovitch ◽  
Elise Herlihy ◽  
Susan Harkema
Keyword(s):  
Multiple Sclerosis ◽  
Body Weight ◽  
Walking Speed ◽  
Functional Mobility ◽  
Body Weight Support ◽  
Locomotor Training ◽  
Weight Support ◽  
Disability Status ◽  
Potential Benefits

Rationale The purpose of this protocol was to investigate the potential benefits and tolerability of locomotor training using body weight support on a treadmill (LTBWST) in persons with multiple sclerosis (MS). Methods Four persons with primarily spinal cord MS and severely impaired ambulation (Expanded Disability Status Scale score 7.0–7.5) were enrolled in LTBWST. Subjects completed an average of 40 training sessions over several months. Results Subjects showed improvement in muscle strength, spasticity, endurance, balance, walking speed, and quality of life at the end of the training sessions, and could tolerate training without fatigue or other adverse effects. Conclusions LTBWST is well tolerated by persons with MS and may produce improvements in parameters related to functional mobility. Multiple Sclerosis 2007; 13: 224–231. http://msj.sagepub.com

Sign in / Sign up

Export Citation Format

Share Document